• Starling Oncology subsidiary SOM entered a revolving loan agreement with Gemino Healthcare Finance’s SLR Healthcare ABL for up to USD 25 million.
• USD 4.75 million was outstanding at closing on Aug. 21, 2026; proceeds earmarked for working capital, general corporate purposes.
• Facility matures Aug. 20, 2029; borrowings priced at Term SOFR + 3.95% with a 2% Term SOFR floor.
• Loan secured by a first-priority lien on substantially all SOM collateral; availability tied to an accounts receivable borrowing base.
• Default rate adds 5%; early termination fee steps down from 3% to 1% of commitments over the term.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Starling Oncology Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001079973-26-001169), on August 21, 2026, and is solely responsible for the information contained therein.